Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trigate study: sapanisertib in NFE2L2-mutated metastatic smoking-related squamous cell carcinoma
jRCT2031220125Phase 2Suspended
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sapanisertib in Pulmonary squamous cell carcinoma, head and neck squamous cell carcinoma (HNSCC) and Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoint: Objective response rate. Started Mar 2023; status: suspended.
02
Drugs
sapanisertib
03
Conditions
Pulmonary squamous cell carcinomahead and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCT2031220125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220125.